Take­da touts a land­mark head-to-head PhI­I­Ib win over Hu­mi­ra; Al­ler­gan's oral CGRP is now un­der FDA re­view

Take­da $TAK says their drug En­tyvio has beat out Ab­b­Vie’s $AB­BV Hu­mi­ra in a head-to-head study for ul­cer­a­tive col­i­tis. Re­searchers point­ed to a 31.3% re­mis­sion rate for their drug, com­pared to 22.5% for the Hu­mi­ra arm at week 52. The com­pa­ny added that this is the first head-to-head study of 2 bi­o­log­ics for UC.

→ An oral CGRP for mi­graine is now un­der FDA re­view. The drug — ubro­gepant — from Al­ler­gan $AGN is set to help the mil­lions of mi­graine suf­fer­ers who now have a menu of in­jectable pre­ven­ta­tive CGRP treat­ments at their dis­pos­al, but are look­ing for that as-need­ed med­i­cine to deal with the odd mi­graine that sneaks up. The FDA is ex­pect­ed to make its de­ci­sion on the drug — that Al­ler­gan got from Mer­ck $MRK in 2015 — by the fourth quar­ter. If ap­proved, ubro­gepant could po­ten­tial­ly be used in com­bi­na­tion with its an­ti-CGRP in­jectable ri­vals and/or Al­ler­gan’s own ver­sa­tile Botox in­jec­tion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.